Computer Vision has already revolutionized other industries. The vision systems that Constellation builds on are much like the ones that proved effective in sending a driverless car coast-to-coast.
Partly because Constellation’s development relies on existing innovations, this potentially life-saving technology can be demonstrated to the market in less than one year.
Concerns over skin cancer have grown exponentially in recent years. Those with increased risk of skin cancer are spending billions annually on dermatologist visits and mole removal, and spending on sunscreen products and SPF clothing continues to climb. Despite the growing awareness and spending, skin cancer rates increase every year.
In 2011, revenues in the U.S. dermatology market climbed to approximately $10 billion.¹
IBISWorld cites high skin cancer rates as a driving force in the $1 billion U.S. sunscreen market.²
In terms of incidence rates, melanoma is one of the fastest growing cancers. The American Cancer Society estimates that 76,690 people in the United States will be diagnosed with melanoma in 2013.
According to the Pew Research Center, one in three American adults are “online diagnosers,” or have gone online to help determine if they have a medical condition.³ As technology has become more advanced, consumers want to take control over their health. Demand for at-home diagnostic tools has grown, and more and more smartphone apps are promising to alert consumers to possible signs of skin cancer. While these apps are growing in popularity, they are extremely limited in their effectiveness. Constellation is in an entirely different category, providing whole-body scanning, flagging subtle mole changes, and promising to change the future of early skin cancer detection resulting in easier treatment.
1. Source: Dermatologists in the US: Market Research Report.” IBISWorld, Dec 2011.
2. Source: Sunscreen Manufacturing in the US: Market Research Report.” IBISWorld, Nov 2012.
3. Source: Health Online 2013.” Pew Research Center’s Internet & American Life Project, January 15, 2013.
When detected early, skin cancer has a cure rate of 99%. But without early detection, survival rates for melanoma plummet. After metastasis, there is virtually no effective treatment for melanoma skin cancer.
Mole changes are the clearest indicators of possible skin cancer. These changes can be subtle and rather rapid, occurring between dermatologist visits. According to the Melanoma Research Foundation (MRF), the majority of melanomas are found by patients, not by physicians.
Constellation gives patients a powerful new way to perform monthly scans that monitor hundreds of moles, virtually everywhere on the body, and detect even subtle changes.
An affordable price point puts Constellation within reach of a sizeable consumer segment that will welcome a way to conduct quick, monthly scans in the privacy of their homes. Commercial segments also offer diversified revenue opportunities:
In addition, Constellation lends itself to mobile screening programs aimed at underserved, high-risk populations such as agricultural workers.
Constellation leverages existing technology in groundbreaking ways. Leading scientists from MIT and Harvard are among those lending their depth of expertise to this project.
Darrell S. Rigel, MD; Robert J. Friedman, MD; Alfred W. Kopf, MD; David Polsky, MD
Arch Dermatol. 2005;141(8):1032-1034. doi:10.1001/archderm.141.8.1032.
The American Academy of Dermatology and the Centers for Disease Control and Prevention
Supplement to the Journal of the American Academy of Dermatology, November 2011.
Gachon, J; Beaulieu P; Sei JF; Gouvernet J; Claudel J; Lemaitre M; Richard MA; Grob JJ
Arch Dermatol. 2005 Apr;141(4):434-8.
Howard K. Koh, MD; Alan C. Geller; Donald R. Miller, ScD; Ted A. Grossbart, PhD; Robert A. Lew, PhD
Arch Dermatol. 1996;132(4):436-443. doi:10.1001/archderm.
Scope A; Dusza SW; Halpern AC; Rabinovitz H; Braun RP; Zalaudek I; Argenziano G; Marghoob AA
Arch Dermatol. 2008 Jan;144(1):58-64. doi: 10.1001/archdermatol.2007.15.
FOUNDER AND CEO
Christian is the Founder of Curated Innovation, a Cambridge-based innovation lab which brings together leading university scientists, donors, and investors to create technology that will make an impact on a health issue they care about. Previously, he invested in spinouts from MIT and Harvard. Before that, he founded and co-led two technology companies: Lincoln Group, acquired by GPI; and Akaru, an early Software-as-a-Service company. Christian holds a BA and MA in Economics and Management from the University of Oxford. He completed studies in molecular biology and materials science as a Fellow at MIT. Charitable activities include serving as a coach for United Way Youth Venture. At his core, Christian is dedicated to solving technology challenges that impact humanity.
© 2013 All Rights Reserved, designed by TeoThemes